Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.

In the C1-INH(SC) 40 IU/kg treatment group, mean changes from baseline demonstrated a trend for improvement but did not reach statistical significance (EQ-5D Health State Value, mean [95% CI] change from baseline 0.03 [0, 0.06]; VAS, 4.33 [− 0.13, 8.80]) (Fig. 2 ).

also in 111,027 other papers